Lima Martínez Marcos M, Contreras Miguel A, Marín Waleskha, D'Marco Luis
Unidad de Endocrinología, Diabetes, Metabolismo y Nutrición, Anexo Centro Médico Orinoco, Ciudad Bolívar, Venezuela; Departamento de Ciencias Fisiológicas, Universidad de Oriente, Núcleo Bolívar, Ciudad Bolívar, Venezuela.
Centro Médico El Valle, Nueva Esparta, Venezuela.
Clin Investig Arterioscler. 2020 Nov-Dec;32(6):278-281. doi: 10.1016/j.arteri.2020.06.003. Epub 2020 Jul 2.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of coronavirus disease 2019 (COVID-19). Acute respiratory distress syndrome is the main cause of death from COVID-19 and occurs due to an exaggerated inflammatory response that causes the release of pro-inflammatory cytokines such as interleukins and tumor necrosis factor-alpha (TNF-α). Statins are lipid lowering drugs with pleiotropic effects. They have shown benefit in the management of inflammatory and autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. Furthermore, due to their immunomodulatory properties, they have been used in the treatment of various infectious diseases such as community-acquired pneumonia and influenza. In this review we analyze the pathophysiological foundations that support the use of statins as an adjunctive treatment in patients with COVID-19.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是2019冠状病毒病（COVID-19）的病原体。急性呼吸窘迫综合征是COVID-19的主要死因，其发生是由于过度的炎症反应导致促炎细胞因子如白细胞介素和肿瘤坏死因子-α（TNF-α）的释放。他汀类药物是具有多效性的降脂药物。它们已显示出在治疗炎症性和自身免疫性疾病如系统性红斑狼疮、类风湿性关节炎和多发性硬化症方面的益处。此外，由于其免疫调节特性，它们已被用于治疗各种传染病，如社区获得性肺炎和流感。在本综述中，我们分析了支持他汀类药物作为COVID-19患者辅助治疗药物的病理生理基础。
